New Molecular Assay RediScore®
RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability.
HerediGENE is a test that fully analyzes a panel of 52 genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
PrIME is a cancer molecular test that incorporates a 500+ tumor-related multi-gene panel associated with targeted therapies. Furthermore, it includes four major biomarkers (PD-L1, MSI, TMB and LOH) related to immunotherapy response and PARP inhibitors' response.
Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Personalized pharmacotherapy based on human DNA.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze the genes associated with inherited cardiovascular disease.
are a series of clinically verified, highly sensitive and specific multi-gene tests that analyze genes associated with hereditary neurological and developmental disorders.
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
The iGenome gene test analyzes more than 20,000 genes associated with inherited diseases, helping the doctor diagnose diseases with unclear phenotypes and antenatal care.
Genekor is a Molecular Biology Laboratory, focused in Oncology, Cardiology, Neurology and Pharmacogenetics. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Medicine sector. A passionate team sharing the same vision on quality healthcare and molecular science is working together in order to provide patients and physicians with reliable actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in Oncology, Cardiology, Neurology and Pharmacogenetics.
See Genekor' s publications and posters.
RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability.
RediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability. It is based on the technology of SNP (Single Nucleotide Polymotphisms), which is the standard method for the analysis of abnormal chromosomal structures formed as a result of the Homologous Recombination Deficiency. Combined with the analysis of mutations of the BRCA1 / 2 genes in the tumor, it gives us a comprehensive picture of the functionality of the HR pathway.
When is RediScore Test Significant?
The RediScore® test is recommended for all patients with ovarian cancer, but also where the use of PARP inhibitors is under investigation for treatment or maintenance treatment of the patient.
Why is The RediScore Test Significant?
It has now been proven by a plethora of clinical studies that about 50% of ovarian cancer patients could benefit from the administration of PARP inhibitors. These include patients with:
»BRCA1 / 2 mutations
»Tumors with homologous recombination deficiency (HRD)
Since 2014, four PARP inhibitors (PARPi) have been approved by the FDA: Olaparib, Niraparib, Rucaparib, and Talazoparib. Their administration has been approved for 4 types of cancer: ovarian, prostate, pancreatic and breast cancer.
Sample type - Tissue enclosed in a paraffin block
Delivery time - 15 working days
Learn more about the assay: https://www.genekor.com/en/services/rediscore/
Please contact Genekor Customer Service for more information on testing. info@genekor.com - Tel: 210 6032138
06.07.2022